Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

NCT01229150 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

NIH

Sponsor class

Conditions

Non Small Cell Lung Carcinoma

Interventions

DRUG: AZD6244
DRUG: Erlotinib
DRUG: AZD6244 + Erlotinib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]